Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KRP-A218 in Healthy Subjects
NCT04908800Phase 1Completed
- Sponsor
- Kyorin Pharmaceutical
- Start
- May 2021
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KRP-A218 in rhinovirus infection (3 arms), sponsored by Kyorin Pharmaceutical. Primary endpoints: Number of Participants With Adverse Events, Area Under Concentration-time Curve From Time 0 Extrapolated to Infinity at Day 1 and 6 more. Started May 2021; status: completed.
02
Drugs
KRP-A218
03
Conditions
rhinovirus infection
Beyond the preview
Go deeper on NCT04908800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908800.